Format

Send to

Choose Destination
J Peripher Nerv Syst. 2011 Jun;16 Suppl 1:14-7. doi: 10.1111/j.1529-8027.2011.00299.x.

Biomarkers of CIDP in patients with diabetes or CMT1.

Author information

1
Department of Neurology and Neuroscience, Weill Medical College of Cornell University, 1305 York Avenue, New York, NY 10021, USA. nol2002@med.cornell.edu

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease that targets the myelin sheaths in peripheral nerves. Primary demyelination can be detected by electrodiagnostic studies or nerve biopsy, but these do not distinguish between demyelination resulting from CIDP or from non-inflammatory causes such as diabetes or Charcot-Marie-Tooth type I. Consequently, the diagnosis of CIDP in such patients is often missed. Studies are needed to establish electrodiagnostic criteria for CIDP in patients with diabetes, and to identify biomarkers that distinguish between inflammatory and non-inflammatory causes of demyelinating neuropathy.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center